Home › Mitral Valve Insufficiency › NCT06738615

Assessing the Relationship Between Symptoms and Mitral Regurgitnant. Severity

Assessing the Impact of Diastolic Dysfunction on the Presence of Symptoms in Patients with Primary Mitral Regurgitation.

Who can join

Ages 18 and older · Men

Inclusion Criteria:

* Age \>=18 years of age
* Able to give informed consent
* Primary (degenerative) mitral regurgitation
* LVEF \>=50%
* Undergoing cardiac catheterization
* Able to exercise on a treadmill

Exclusion Criteria:

* Unable to give informed consent
* Secondary (functional) mitral regurgitation
* LVEF \<50%
* Known coronary artery stenosis \>=70% or past revascularization
* More than mild aortic stenosis, mitral stenosis, aortic regurgitation, tricuspid regurgitation, or pulmonic regurgitation
* Hypertrophic cardiomyopathy
* Pregnancy

About the study

The current American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend surgery in patient with mitral regurgitation (MR) based on 1) the severity of MR and 2) the presence or absence of symptoms. Studies have shown that Cardiovascular Magnetic Resonance (CMR) is an accurate method to quantify the severity of MR. However, studies have also shown that symptoms are not necessarily related to the presence of symptoms. Thus, there appears to be a disconnect between the severity of MR and symptoms. Recent analysis of our data has shown that females and older patients with smaller ventricles, lower stroke volumes, and lower regurgitant volume relative to regurgitant fraction tend to be symptomatic. These findings suggest that decreased left ventricular compliance, i.e. diastolic dysfunction, may play an important role as an etiology of symptoms in patients with mitral regurgitation. The aim of this study is to study the presence of diastolic dysfunction in patients with MR and its association with symptom burden and exercise capacity.

What is being tested

• Pressure volume loop evaluation (diagnostic test)
• cardiovascular magnetic resonance imaging (diagnostic test)
• Cardiopulmonary exercise testing (CPET) (diagnostic test)
• Kansas City Cardiomyopathy Questionairre (diagnostic test)

Sponsor: Atlantic Health System · Participants: 40 · Started: Jan 2, 2025

Contact the study team

• Medical Director, Cardiovascular Imaging, MD · Phone: 9739715597

Official record on ClinicalTrials.gov — NCT06738615

Locations in the U.S.

Conditions

• Mitral Valve Insufficiency

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.